OBJECTIVE: To evaluate the therapeutic efficacy of uncultured bone marrow mononuclear cells (BMMCs) and bone mesenchymal stem cells in an osteoarthritis (OA) model of sheep. METHODS: Induction of sheep OA was performed surgically through anterior cruciate ligament transection and medial meniscectomy. After 12 weeks, concentrated BMMCs obtained from autologous bone marrow harvested from anterior iliac crest or a single dose of 10 million autologous bone mesenchymal stem cells (BMSCs) suspended in phosphate-buffered saline (PBS) was delivered to the injured knee via direct intra-articular injection. Animals of the PBS group received vehicle alone. The contra-lateral joints were selected randomly as the control group. Knees of the four groups were compared macroscopically and histologically, and glycosaminoglycan (GAG) contents normalized to cartilage wet weight were measured at lesions of cartilage from medial condyle of the femur head. Gene expression levels of type II collagen (Col2A1), Aggrecan and matrix metalloproteinase-13 (MMP-13) in cartilage were measured based on RT-PCR and prostaglandin E2 (PGE2), Tumor Necrosis Factor-α (TNF-α) and Transforming Growth Factor beta (TGF-β) concentrations in synovial fluid were determined with ELISA assays at 8 weeks after injection. RESULTS: At 8 weeks post cell transplantation, partial cartilage repair was observed in the cell therapy, but not the PBS group (P<0.05). The BMSCs group showed higher regeneration of cartilage and lower proteoglycan loss than the BMMCs group (P<0.05). Concentrated BMMCs injection led to a weaker treatment effect, but also inhibited PGE2, TNF-α and TGF-β levels in synovial fluid and promoted higher levels of Aggrecan and Col2A1 and downregulation of MMP-13 in sheep chondrocytes in a similar manner to BMSCs, compared with the PBS group. CONCLUSIONS: Bone marrow cells showed therapeutic efficacy in a sheep model of OA. Despite similar therapeutic potential, the easier and faster process of collection and isolation of BMMCs supports their utility as an effective alternative for OA treatment in the clinic.
OBJECTIVE: To evaluate the therapeutic efficacy of uncultured bone marrow mononuclear cells (BMMCs) and bone mesenchymal stem cells in an osteoarthritis (OA) model of sheep. METHODS: Induction of sheep OA was performed surgically through anterior cruciate ligament transection and medial meniscectomy. After 12 weeks, concentrated BMMCs obtained from autologous bone marrow harvested from anterior iliac crest or a single dose of 10 million autologous bone mesenchymal stem cells (BMSCs) suspended in phosphate-buffered saline (PBS) was delivered to the injured knee via direct intra-articular injection. Animals of the PBS group received vehicle alone. The contra-lateral joints were selected randomly as the control group. Knees of the four groups were compared macroscopically and histologically, and glycosaminoglycan (GAG) contents normalized to cartilage wet weight were measured at lesions of cartilage from medial condyle of the femur head. Gene expression levels of type II collagen (Col2A1), Aggrecan and matrix metalloproteinase-13 (MMP-13) in cartilage were measured based on RT-PCR and prostaglandin E2 (PGE2), Tumor Necrosis Factor-α (TNF-α) and Transforming Growth Factor beta (TGF-β) concentrations in synovial fluid were determined with ELISA assays at 8 weeks after injection. RESULTS: At 8 weeks post cell transplantation, partial cartilage repair was observed in the cell therapy, but not the PBS group (P<0.05). The BMSCs group showed higher regeneration of cartilage and lower proteoglycan loss than the BMMCs group (P<0.05). Concentrated BMMCs injection led to a weaker treatment effect, but also inhibited PGE2, TNF-α and TGF-β levels in synovial fluid and promoted higher levels of Aggrecan and Col2A1 and downregulation of MMP-13 in sheep chondrocytes in a similar manner to BMSCs, compared with the PBS group. CONCLUSIONS: Bone marrow cells showed therapeutic efficacy in a sheep model of OA. Despite similar therapeutic potential, the easier and faster process of collection and isolation of BMMCs supports their utility as an effective alternative for OA treatment in the clinic.
Authors: Andrew C Boquest; Aboulghassem Shahdadfar; Katrine Frønsdal; Olafur Sigurjonsson; Siv H Tunheim; Philippe Collas; Jan E Brinchmann Journal: Mol Biol Cell Date: 2005-01-05 Impact factor: 4.138
Authors: Andréia Vasconcelos-dos-Santos; Paulo Henrique Rosado-de-Castro; Sergio Augusto Lopes de Souza; Juliana da Costa Silva; Alane Bernardo Ramos; Gabriel Rodriguez de Freitas; Lea Mirian Barbosa da Fonseca; Bianca Gutfilen; Rosalia Mendez-Otero Journal: Stem Cell Res Date: 2012-02-28 Impact factor: 2.020
Authors: Abir N Mokbel; Omar S El Tookhy; Ashraf A Shamaa; Laila A Rashed; Dina Sabry; Abeer M El Sayed Journal: BMC Musculoskelet Disord Date: 2011-11-15 Impact factor: 2.362
Authors: Mukundan Attur; Jonathan Samuels; Svetlana Krasnokutsky; Steven B Abramson Journal: Best Pract Res Clin Rheumatol Date: 2010-02 Impact factor: 4.098
Authors: Christopher J Centeno; Dan Busse; John Kisiday; Cristin Keohan; Michael Freeman; David Karli Journal: Pain Physician Date: 2008 May-Jun Impact factor: 4.965
Authors: S C Mendes; J M Tibbe; M Veenhof; K Bakker; S Both; P P Platenburg; F C Oner; J D de Bruijn; C A van Blitterswijk Journal: Tissue Eng Date: 2002-12
Authors: Marcelo M Cardoso; Edna C S Franco; Celice C de Souza; Michelle C da Silva; Amauri Gouveia; Walace Gomes-Leal Journal: Inflammation Date: 2013-02 Impact factor: 4.092
Authors: Hayam G Sayyed; Amany Osama; Naglaa K Idriss; Dina Sabry; Azza S Abdelrhim; Rania Bakry Journal: Int J Physiol Pathophysiol Pharmacol Date: 2016-09-30
Authors: Gonzalo Piñero; Vanina Usach; Paula A Soto; Paula V Monje; Patricia Setton-Avruj Journal: Transgenic Res Date: 2018-02-16 Impact factor: 2.788
Authors: P Tangchitphisut; N Srikaew; S Numhom; A Tangprasittipap; P Woratanarat; S Wongsak; C Kijkunasathian; S Hongeng; I R Murray; T Tawonsawatruk Journal: Arthritis Date: 2016-04-26
Authors: Clara Sanjurjo-Rodríguez; Rocío Castro-Viñuelas; Tamara Hermida-Gómez; Tania Fernández-Vázquez; Isaac Manuel Fuentes-Boquete; Francisco Javier de Toro-Santos; Silvia María Díaz-Prado; Francisco Javier Blanco-García Journal: PLoS One Date: 2017-01-31 Impact factor: 3.240
Authors: Niina Hopper; John Wardale; Roger Brooks; Jonathan Power; Neil Rushton; Frances Henson Journal: PLoS One Date: 2015-08-07 Impact factor: 3.240